Qualcomm Stock: 5G Leader at a Bargain Price?
Chip giant QUALCOMM Incorporated (NASDAQ:QCOM) was the ultimate chip company…
Sell
32
EW Quote, Financials, Valuation and Earnings
Last price:
$69.25
Seasonality move
:
8.76%
Day range:
$67.78 - $69.66
52-week range:
$58.93 - $96.12
Dividend yield:
0%
P/E ratio:
9.94x
P/S ratio:
7.25x
P/B ratio:
4.07x
Volume:
3.5M
Avg. volume:
4.4M
1-year change:
-25.78%
Market cap:
$40.7B
Revenue:
$5.4B
EPS (TTM):
$6.97
Analysts' Opinion
-
Consensus RatingEdwards Lifesciences has received a consensus rating of Hold. The company's average rating is a Hold based on 10 Buy ratings, 17 Hold ratings, and 1 Sell rating.
-
Price Target UpsideAccording to analysts' consensus price target of $80.42, Edwards Lifesciences has an estimated upside of 16.07% from its current price of $69.29.
-
Price Target DownsideAccording to analysts, the lowest downside price target is $61.00 representing 100% downside risk from its current price of $69.29.
Fair Value
-
According to the consensus of 28 analysts, Edwards Lifesciences has 16.07% upside to fair value with a price target of $80.42 per share.
EW vs. S&P 500
-
Over the past 5 trading days, Edwards Lifesciences has overperformed the S&P 500 by 2.96% suggesting its relative strength compared to the major market average is strong at this time.
Share Buyback
-
Edwards Lifesciences does have a share repurchase program in place at this time. The scale of a buyback program can materially affect share price and usually results in a higher earnings per share, all else being equal, when the share count drops.
Revenue Growth
-
Edwards Lifesciences has grown year-over-year revenues for 5 quarters straight. In the most recent quarter Edwards Lifesciences reported revenues of $1.4B.
Earnings Growth
-
Edwards Lifesciences has grown year-over-year earnings for 4 quarters straight. In the most recent quarter Edwards Lifesciences reported earnings per share of $0.65.
Enterprise value:
37.4B
EV / Invested capital:
3.51x
Price / LTM sales:
7.25x
EV / EBIT:
22.68x
EV / Revenue:
6.54x
PEG ratio (5yr expected):
0.05x
EV / Free cash flow:
143.99x
Price / Operating cash flow:
159.77x
Enterprise value / EBITDA:
20.73x
Gross Profit (TTM):
$4.5B
Return On Assets:
37.8%
Net Income Margin (TTM):
72.93%
Return On Equity:
50.81%
Return On Invested Capital:
47.36%
Operating Margin:
25.49%
| Trailing 12 Months | Fiscal Quarters | |||||
|---|---|---|---|---|---|---|
| Period Ending | 2022-12-31 | 2023-12-31 | 2024-12-31 | 2023-12-31 | 2024-12-31 | |
| Income Statement | ||||||
| Revenue | $4.5B | $5.3B | $5.7B | $1.3B | $1.4B | |
| Gross Profit | $3.7B | $4.2B | $4.5B | $1B | $1.1B | |
| Operating Income | $1.5B | $1.5B | $1.6B | $356.7M | $353.3M | |
| EBITDA | $1.7B | $1.6B | $1.8B | $297.2M | $483.7M | |
| Diluted EPS | $2.44 | $2.30 | $6.97 | $0.61 | $0.65 | |
| Period Ending | 2020-12-31 | 2021-12-31 | 2022-12-31 | 2023-12-31 | 2024-12-31 | |
|---|---|---|---|---|---|---|
| Balance Sheet | ||||||
| Current Assets | $3.1B | $3.2B | $3.1B | $4B | $6.3B | |
| Total Assets | $7.2B | $8.5B | $8.3B | $9.4B | $13.1B | |
| Current Liabilities | $893.9M | $1B | $1B | $1.2B | $1.5B | |
| Total Liabilities | $2.7B | $2.7B | $2.5B | $2.6B | $3B | |
| Total Equity | $4.6B | $5.8B | $5.8B | $6.7B | $10.1B | |
| Total Debt | $595M | $595.7M | $596.3M | $597M | $597.7M | |
| Trailing 12 Months | Fiscal Quarters | |||||
|---|---|---|---|---|---|---|
| Period Ending | 2022-12-31 | 2023-12-31 | 2024-12-31 | 2023-12-31 | 2024-12-31 | |
| Cash Flow Statement | ||||||
| Cash Flow Operations | $1.2B | $895.8M | $542.3M | $136.6M | -$127.5M | |
| Cash From Investing | $252.3M | $173.8M | $2.3B | $14.1M | -$576.7M | |
| Cash From Financing | -$1.6B | -$711M | -$983M | -$413.2M | $28.6M | |
| Free Cash Flow | $953.4M | $629.5M | $259.9M | $48.3M | -$181.9M | |
EW
Sector
Market Cap
$40.7B
$38.4M
Price % of 52-Week High
72.09%
45.53%
Dividend Yield
0%
0%
Shareholder Yield
2.66%
-0.78%
1-Year Price Total Return
-25.78%
-39.05%
Beta (5-Year)
1.123
0.774
Dividend yield:
0%
Annualized payout:
$0.00
Payout ratio:
--
Growth streak:
0 years
SEE THE 1% OF STOCKS YOU NEED TO OWN FOR MASSIVE RETURNS
GET BETTER TRADE IDEAS
Technicals
8-day SMA
Sell
Level
$70.06
200-day SMA
Sell
Level
$73.67
Bollinger Bands (100)
Sell
Level
68.5 - 73.78
Chaikin Money Flow
Buy
Level
153.7M
20-day SMA
Sell
Level
$72.23
Relative Strength Index (RSI14)
Sell
Level
41.60
ADX Line
Sell
Level
18.38
Williams %R
Neutral
Level
-66.4681
50-day SMA
Sell
Level
$71.91
MACD (12, 26)
Sell
Level
-0.92
25-day Aroon Oscillator
Sell
Level
-72
On Balance Volume
Neutral
Level
179.4M
Financial Scores
Buy
Altman Z-Score
(Annual)
Level (11.4013)
Buy
CA Score
(Annual)
Level (1.4695)
Buy
Beneish M-Score
(Annual)
Level (-2.2599)
Buy
Momentum Score
Level (4)
Buy
Ohlson Score
Level (-4.7887)
Buy
Piotroski F Score
(Annual)
Level (6)
Buy
Quality Ratio Score
Level (5)
Buy
Fundamental Score
Level (9)
Revenue Forecast
Earnings per Share Forecast
Company Profile
Spun off from Baxter International in 2000, Edwards Lifesciences designs, manufactures, and markets a range of medical devices and equipment for advanced stages of structural heart disease. It has established itself as a leader across key products, including surgical tissue heart valves, transcatheter aortic valves, and transcatheter mitral and tricuspid valve technologies. The firm derives about 60% of its total sales from outside the US.
Stock Forecast FAQ
In the current month, EW has received 10 Buy ratings 17 Hold ratings, and 1 Sell ratings. The EW average analyst price target in the past 3 months is $80.42.
-
Where Will Edwards Lifesciences Stock Be In 1 Year?
According to analysts, the consensus estimate is that Edwards Lifesciences share price will rise to $80.42 per share over the next 12 months.
-
What Do Analysts Say About Edwards Lifesciences?
Analysts are divided on their view about Edwards Lifesciences share price and where it will be in the next 12 months. The majority of analysts rate the stock a Buy. However, a smaller subset of analysts suggest that Edwards Lifesciences is a Sell and believe this share price will drop from its current level to $61.00.
-
What Is Edwards Lifesciences's Price Target?
The price target for Edwards Lifesciences over the next 1-year time period is forecast to be $80.42 according to 28 Wall Street analysts, 10 of them rate the stock a Buy, 1 rates the stock a Sell, and 17 analysts rate the stock a Hold.
-
Is EW A Buy, Sell Or Hold?
According to Wall Street analysts, the consensus rating for Edwards Lifesciences is a Hold. 17 of 28 analysts rate the stock a Hold at this time.
-
How Can I Buy Shares Of EW?
You can purchase shares of Edwards Lifesciences via an online brokerage firm such as TD Ameritrade.com, thinkorswim.com, e-trade.com, tastytrade.com, or Schwab.com. Many other digital online brokerages exist such as RobinHood and Webull where you can purchase Edwards Lifesciences shares.
-
What Is The Edwards Lifesciences Share Price Today?
Edwards Lifesciences was last trading at $69.25 per share. This represents the most recent stock quote for Edwards Lifesciences. Yesterday, Edwards Lifesciences closed at $69.29 per share.
-
How To Buy Edwards Lifesciences Stock Online?
In order to purchase Edwards Lifesciences stock online, open a brokerage account, deposit funds into the account, and select an order type to purchase shares whether it be market or limit.
SEE THE 1% OF STOCKS YOU NEED TO OWN FOR MASSIVE RETURNS
GET BETTER TRADE IDEAS
Popular
What Is Buffett Buying and Selling Now?
In Q4 of last year, Warren Buffett made a few…
3 Safest Stocks to Buy Now
With the S&P 500 now in correction and stocks selling…
Stock Ideas
Buy
52
Is AAPL Stock a Buy?
Market Cap: $3.2T
P/E Ratio: 35x
Buy
56
Is NVDA Stock a Buy?
Market Cap: $3T
P/E Ratio: 41x
Buy
51
Is MSFT Stock a Buy?
Market Cap: $2.9T
P/E Ratio: 33x
Alerts
Buy
59
GRRR alert for Mar 15
Gorilla Technology Group [GRRR] is up 29.72% over the past day.
Buy
62
PLPC alert for Mar 15
Preformed Line Products [PLPC] is up 17.38% over the past day.
Sell
50
NUTX alert for Mar 15
Nutex Health [NUTX] is up 14.56% over the past day.
